ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (35)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Celli, B. R.
Right arrow Articles by Barnes, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Celli, B. R.
Right arrow Articles by Barnes, P. J.
Eur Respir J 2007; 29:1224-1238
Copyright ©ERS Journals Ltd 2007

Exacerbations of chronic obstructive pulmonary disease

B. R. Celli1 and P. J. Barnes2

1 Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA. 2 National Heart and Lung Institute, Imperial College, London, UK.

CORRESPONDENCE: P. J. Barnes, Airway Disease Section, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK. Fax: 44 2073515675. E-mail: p.j.barnes{at}imperial.ac.uk

Keywords: Bacterial infection, exacerbation, health status, inflammation, viral infection

Received: August 23, 2006
Accepted February 15, 2007

Exacerbations of chronic obstructive pulmonary disease are of major importance in terms of their prolonged detrimental effects on patients, the acceleration in disease progression and high healthcare costs.

There is still debate about how exacerbations should be defined and graded, and their mechanisms are poorly understood. The major causal agents are either bacteria or viral infections, or a combination of the two. Noninfective causes include air pollution and pulmonary embolus but, in some patients, no cause is identified.

Exacerbations represent an increase in the inflammation that is present in the stable state, with increased numbers of inflammatory cells (particularly neutrophils), cytokines, chemokines and proteases in the airways, and increased concentrations of certain cytokines and C-reactive protein in the blood. There are presently no reliable biomarkers with which to predict exacerbations.

Exacerbations have a long-lasting adverse influence on health status. High doses of bronchodilators are the mainstay of treatment and systemic corticosteroids have some benefit. The routine use of antibiotics remains controversial but they are of benefit with exacerbations of a bacterial origin. Noninvasive ventilation is beneficial in preventing the need for intubation and its important complications but it is not certain whether its use in stable patients prevents exacerbations. Although important advances have been made, more effective treatments are needed in the future for prevention and treatment of exacerbations.




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
F. Luppi, B. Beghe, and L. Richeldi
Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Are Antibiotics Needed?
Am. J. Respir. Crit. Care Med., January 15, 2010; 181(2): 102 - 103.
[Full Text] [PDF]


Home page
ERRHome page
A. Bourdin, P-R Burgel, P. Chanez, G. Garcia, T. Perez, and N. Roche
Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities
Eur. Respir. Rev., December 1, 2009; 18(114): 198 - 212.
[Full Text] [PDF]


Home page
ChestHome page
M. M. de Oca, C. Talamo, R. J. Halbert, R. Perez-Padilla, M. V. Lopez, A. Muino, J. R. B. Jardim, G. Valdivia, J. Pertuze, D. Moreno, et al.
Frequency of Self-Reported COPD Exacerbation and Airflow Obstruction in Five Latin American Cities: The Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) Study
Chest, July 1, 2009; 136(1): 71 - 78.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
C. J. Jolley and J. Moxham
A physiological model of patient-reported breathlessness during daily activities in COPD
Eur. Respir. Rev., June 1, 2009; 18(112): 66 - 79.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
A. Lacoma, C. Prat, F. Andreo, and J. Dominguez
Biomarkers in the management of COPD
Eur. Respir. Rev., June 1, 2009; 18(112): 96 - 104.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P.-R. Burgel, P. Nesme-Meyer, P. Chanez, D. Caillaud, P. Carre, T. Perez, N. Roche, and on behalf of the Initiatives Bronchopneumopathie C
Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects
Chest, April 1, 2009; 135(4): 975 - 982.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Vitacca, L. Bianchi, A. Guerra, C. Fracchia, A. Spanevello, B. Balbi, and S. Scalvini
Tele-assistance in chronic respiratory failure patients: a randomised clinical trial
Eur. Respir. J., February 1, 2009; 33(2): 411 - 418.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. G. Foreman, D. L. DeMeo, C. P. Hersh, V. J. Carey, V. S. Fan, J. J. Reilly, S. D. Shapiro, and E. K. Silverman
Polymorphic variation in surfactant protein B is associated with COPD exacerbations
Eur. Respir. J., October 1, 2008; 32(4): 938 - 944.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, D. Miedinger, J. Leuppi, C. Muller, R. Bingisser, J. Struck, B. Muller, and M. Tamm
Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD
Chest, August 1, 2008; 134(2): 263 - 272.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. M. Clini and N. Ambrosino
Nonpharmacological treatment and relief of symptoms in COPD
Eur. Respir. J., July 1, 2008; 32(1): 218 - 228.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. R. Celli
Update on the Management of COPD
Chest, June 1, 2008; 133(6): 1451 - 1462.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
N. MacIntyre and Y. C. Huang
Acute Exacerbations and Respiratory Failure in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 530 - 535.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Gonzalez, E. Servera, and J. Marin
Importance of Noninvasively Measured Respiratory Muscle Overload Among the Causes of Hospital Readmission of COPD Patients
Chest, April 1, 2008; 133(4): 941 - 947.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Churg, M. Cosio, and J. L. Wright
Mechanisms of cigarette smoke-induced COPD: insights from animal models
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L612 - L631.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
A. R. Leff and N. M. Munoz
Future Treatment to Lessen Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 659 - 666.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. P. Tashkin
Oral vs IV Corticosteroids for In-hospital Treatment of COPD Exacerbations
Chest, December 1, 2007; 132(6): 1728 - 1729.
[Full Text] [PDF]


Home page
Eur Respir JHome page
A. Singh
Beyond the "ABC approach"
Eur. Respir. J., October 1, 2007; 30(4): 812 - 812.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the European Respiratory Society.